Trials / Completed
CompletedNCT02079727
Condrosulf vs Celebrex vs Placebo in the Treatment of Knee OA
A Multicentre, Comparative, Randomised, Double-blind, Double-dummy Clinical Trial on the Efficacy and Safety of Condrosulf Versus Celebrex and Versus a Placebo in the Treatment of Knee Osteoarthritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 604 (actual)
- Sponsor
- IBSA Institut Biochimique SA · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to confirm the efficacy and safety of 800 mg Chondroitin 4\&6 sulfate (Condrosulf) vs placebo once a day for 6 months in the symptomatic treatment of knee osteoarthritis. A third group, Celecoxib 200 mg (Celebrex) once a day, will be used as active comparator.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | chondroitin sulfate | |
| DRUG | celecoxib | |
| DRUG | placebo |
Timeline
- Start date
- 2014-06-12
- Primary completion
- 2015-10-19
- Completion
- 2016-06-16
- First posted
- 2014-03-06
- Last updated
- 2017-03-03
Locations
16 sites across 5 countries: Belgium, Czechia, Italy, Poland, Switzerland
Source: ClinicalTrials.gov record NCT02079727. Inclusion in this directory is not an endorsement.